#Biotechnology--Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collabo...

SEATTLE: #Biotechnology--Compvide, Inc., a biotechnology company pioneering functional complement intelligence through innovative diagnostics and immune-response monitoring, today announced a strategic collaboration with OpZira, Inc. to support the company’s continued growth and accelerate development of its proprietary CIMED platform.
Through the collaboration, OpZira will provide comprehensive operational support across clinical, customer care, finance, manufacturing, marketing, quality, and regulatory functions,” stated Clark Tedford, Ph.D., President and CEO, OpZira, Inc. “By leveraging OpZira’s established operational infrastructure and expertise, Compvide can remain focused on advancing its scientific innovation while expanding its capabilities in complement-focused diagnostics and translational medicine.”
“Partnering with an experienced organization that understands the unique needs of emerging healthcare companies is an important step for Compvide as we continue building the company,” said Sadam Yaseen, Ph.D., Founder and CEO of Compvide. “This collaboration expands our execution capacity while allowing us to focus on our mission of enabling more precise treatment decisions through innovative complement science.”
Compvide’s proprietary CIMED platform delivers functional complement intelligence by measuring physiologically relevant complement activity and translating complex immune biology into clinically actionable insights for drug development, therapeutic monitoring, precision medicine, and next-generation diagnostics. The company’s mission is to allow healthcare providers to functionally monitor the major pathways involved in critical complement-mediated and immune-targeted diseases to allow personalized and precision medicine.
About Compvide
Compvide is a Seattle-based biotechnology company pioneering functional complement intelligence through innovative assay development, translational research, and diagnostic technologies. Its proprietary CIMED platform transforms complex complement biology into actionable clinical insights that support drug development, precision medicine, and improved patient care.
About OpZira
OpZira is focused on the early detection and comprehensive monitoring of ocular diseases, with a mission to empower clinicians through innovative technologies that enhance patient care and improve outcomes.
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Circle Internet Group, Inc. (NYSE: CRCL) today announced results for the second quarter of fiscal year 2026. Financial Highlights (Q2’26 vs. Q2’25) USDC…
This week at FMS: the Future of Memory and Storage, KIOXIA America, Inc. will demonstrate how its flash memory and SSD technologies, including the KIOXIA…
Atkore Inc. (“Atkore” or the “Company”) (NYSE: ATKR), a leading manufacturer of electrical infrastructure products, announced today that it has entered…
Iron Mountain Incorporated (NYSE: IRM), a global leader in information management services, announces financial results for the second quarter of 2026.…